Posts Tagged ‘PACAP’
Migraine Basic Science Update: Targets, Antagonists, and More
A wide range of animal studies during the first half of 2025 point to promising new directions for the field.
Read MoreZeroing in on PACAP to Treat Migraine
A phase 2, placebo-controlled clinical trial found that an anti-PACAP antibody decreased monthly migraine days.
Read MoreMid-Year Update: What Have You Been Reading on Migraine Science Collaborative in 2024?
Our Top 5 list reflects interest in new approaches to treating headache.
Read MoreCGRP, PACAP and Beyond: Understanding Current and Future Migraine Treatment Targets – An Interview with Debbie Hay
In this Migraine Science Collaborative interview, Professor Debbie Hay discusses her path to becoming a molecular pharmacologist, her work on GPCRs, and the future of migraine treatment.
Read MorePACAP: A New Target for Treatment of Post-Traumatic Headache?
A recent randomized clinical trial builds the case for pituitary adenylate cyclase-activating polypeptide-38 in the pathophysiology of PTH.
Read MorePACAP Signaling: A New Mechanism of Medication Overuse Headache from Opioids?
A recent animal study shows that inhibiting pituitary adenylate cyclase-activating polypeptide alleviates medication overuse headache following morphine. The findings have interesting translational potential.
Read MorePACAP Goes Its Own Way in Migraine
A new study reports that the PACAP signaling pathway is independent from the CGRP pathway, confirming the promise of PACAP as a drug target for migraine treatment.
Read More